Novoeight FDA Approval History
Novoeight (turoctocog alfa) is an antihemophilic factor (recombinant) indicated for use in adults and children with hemophilia A.
Development Timeline for Novoeight
|Oct 16, 2013||NovoEight (turoctocog alfa) Receives Approval from the FDA|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.